Key Points
- Francis Lo sold 38,074 shares of Adaptive Biotechnologies on March 5 at an average price of $15.09 for $574,536.66, leaving him with 321,967 shares (a 10.57% reduction in his ownership, valued at about $4.86M).
- Lo has been a frequent seller recently, executing additional large sales on Jan 12, Jan 2, Dec 22 and Dec 15 — roughly $3.9 million in aggregate proceeds from these transactions.
- Company fundamentals are mixed: revenue grew 51% year-over-year to $71.7M and results beat estimates, but Adaptive remains unprofitable with negative net margin and return on equity and a market cap near $2.3B.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 38,074 shares of the company's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $15.09, for a total transaction of $574,536.66. Following the sale, the insider directly owned 321,967 shares of the company's stock, valued at approximately $4,858,482.03. This represents a 10.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Francis Lo also recently made the following trade(s):
- On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.73, for a total transaction of $1,411,130.70.
- On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total transaction of $50,250.00.
- On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00.
- On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total value of $1,773,267.30.
Adaptive Biotechnologies Stock Performance
Adaptive Biotechnologies stock opened at $14.95 on Tuesday. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The firm has a market capitalization of $2.30 billion, a PE ratio of -37.37 and a beta of 2.19. The business's 50-day simple moving average is $16.76 and its 200-day simple moving average is $15.87.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm's revenue for the quarter was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.23) EPS. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Hedge Funds Weigh In On Adaptive Biotechnologies
Several hedge funds and other institutional investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies during the third quarter worth $30,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after acquiring an additional 1,565 shares during the period. Assetmark Inc. lifted its holdings in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at $51,000. Institutional investors own 99.17% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on ADPT shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, February 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $18.25.
Check Out Our Latest Stock Analysis on ADPT
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
